Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1701541 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $1.66Day −5.68%Mkt cap $95MP/E (FY) 4.3×1Y −40.3%Off 52W high −66.4%Vol (1Y) 86.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,627 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest10.2% of sh out |
| Days to cover3.7d |
| 13F net flow (QoQ)−0.05% |
| Top-10 13F concentration67.5% |
| Next report (est.)2026-08-04 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)4.3× |
| Sales (TTM)$0 |
| Earnings (TTM)-$43.2M |
| ROE22.9% |
| Net margin32.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−31.7% |
| 1Y−40.3% |
| 3Y−55.5% |
| 5Y−82.2% |
| Since incept. (ann.)−38.6% |
Price return through 2026-07-29 · series begins 2020-01-30. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)86.1% |
| Ann. volatility (3Y)83.0% |
| Sharpe (1Y)−0.22 |
| Sharpe (3Y)0.10 |
| Max drawdown (1Y)−66.9% |
| Max drawdown (3Y)−83.1% |
| Beta (3Y vs SPY)2.99 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 10.6M | $23M | 18.44% | −18.4% |
| NEA Management Company, LLC | 4.4M | $9M | 7.77% | +0.0% |
| ACADIAN ASSET MANAGEMENT LLC | 2.3M | $5M | 4.10% | +44.1% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.9M | $4M | 3.23% | new |
| RENAISSANCE TECHNOLOGIES LLC | 1.6M | $4M | 2.87% | +73.1% |
| DIMENSIONAL FUND ADVISORS LP | 1.3M | $3M | 2.27% | +51.9% |
| BlackRock, Inc. | 1.1M | $2M | 1.93% | +24.6% |
| Connor, Clark & Lunn Investment Management Ltd. | 1.1M | $2M | 1.85% | +61.7% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.16 | −116.3% | $0 | −100.0% |
| 2025-12-31 | 2026-03-16 | — | — | $0 | — |
| 2025-09-30 | 2025-11-06 | −$0.15 | — | $0 | — |
| 2025-06-30 | 2025-08-07 | −$0.19 | — | $0 | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-04 is ESTIMATED from filing cadence (median gap 89d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
